Clinical Trials on Unresectable Stage III or Stage IV Melanoma

Total 4262 results

Emory University
Genentech, Inc.

Active, not recruiting

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IV

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA Melanoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); University of Virginia

Completed

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC Melanoma

United States
William Carson
Schering-Plough

Completed

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
Elizabeth Buchbinder, MD
Genentech, Inc.

Recruiting

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Stage IV Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Unresectable Stage III Cutaneous Melanoma | Unresectable Stage IV Cutaneous Melanoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; Array BioPharma

Recruiting

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditions

United States
Celldex Therapeutics

Terminated

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Unresectable Stage III or Stage IV Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bone Loss in Melanoma Survivors Receiving Immunotherapy

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
CuraGen Corporation

Completed

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Unresectable Stage III or Stage IV Melanoma

United States
Mayo Clinic

Active, not recruiting

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab to Treat Melanoma (Checkmate 168)

Stage III (Unresectable) or Stage IV Advanced Melanoma

United States, Canada, Argentina, Colombia, Peru, Brazil
Roswell Park Cancer Institute

Completed

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IB Skin Melanoma

United States
Leap Therapeutics, Inc.
Cancer Research Institute, New York City

Completed

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)

Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

United States
European Organisation for Research and Treatment...

Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

Stage IV Melanoma | Unresectable Stage III Melanoma

France, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
Sheba Medical Center

Unknown

Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy

Melanoma Stage Iv | Unresectable Stage III Melanoma

Israel
University of California, Irvine
GlaxoSmithKline

Completed

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
National Cancer Institute (NCI)

Completed

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage... and other conditions

United States
Dana-Farber Cancer Institute
Partner Therapeutics (PTx)

Withdrawn

Sargramostim (GM-CSF) + PD-1

Metastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Stage IV Lung Cancer | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Malignant Female Reproductive System Neoplasm | Stage III... and other conditions

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Terminated

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
Yale University
National Cancer Institute (NCI)

Completed

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

FDG-PET in Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Eisai Inc.

Completed

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Stage IV Melanoma | Unresectable Stage III

United States, United Kingdom, Australia, Germany
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant Melanoma

United States
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 408 Capsules in Patients With Melanoma - REVEAL

Melanoma | Unresectable (Stage III) Melanoma | Metastatic (Stage IV) Melanoma

United States
Abramson Cancer Center of the University of Pennsylvania

Terminated

Early FDG PET in Melanoma

Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Metastatic Merkel Cell Carcinoma | Metastatic Skin... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Metastatic Malignant Neoplasm in the Brain | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University Health Network, Toronto

Completed

Study of Ipilimumab in the Immune System

Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma

Canada
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical... and other conditions

United States
Eisai Inc.

Terminated

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Unresectable Stage III Melanoma | Wild Type BRAF Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
National Cancer Institute (NCI)

Completed

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Mucosal Melanoma | Iris Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanoma | Recurrent... and other conditions

United States

Clinical Trials on Unresectable Stage III or Stage IV Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations